| Janssen-Cilag AG - Trevicta 525 mg/2.625 ml, Depot-Injektionssuspension in einer Fertigspritze |
| 66054 | | 04 | | Trevicta 525 mg/2.625 ml | | Depot-Injektionssuspension in einer Fertigspritze | | N05AX13 | | Paliperidone | | 16.11.2016 | | |
|
| Composition |
| paliperidonum 525 mg ut paliperidoni palmitas 819 mg, polysorbatum 20, macrogolum 4000, acidum citricum monohydricum, natrii dihydrogenophosphas monohydricus, natrii hydroxidum, aqua ad iniectabile q.s. ad suspensionem pro 2.625 ml corresp. natrium 10.78 mg. |
| Packungsbestandteile |
| Retardsuspension zur intramuskulären Injektion | | | | | | | | Active Agent | Dose |
|---|
| Paliperidonum | 525mg / 2.625ml |
| | BAG: Active Agent | Dose |
|---|
| Paliperidonum | 525 mg |
| | | | Inactive agents | Dose |
|---|
| Citric Acid Monohydrate | | | Macrogol | 4000 | | Sodium Dihydrogenophosphate Monohydrate | | | Sodium Hydroxide | | | Polysorbatum 20 | |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 004 | | 1722.13 | 1889.35 | B | SL | Yes |
|
